References
- Chave KJ, Ryan TJ, Chmura SE, Galivan J. (2003). Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 319:167–75
- Cronstein BN. (1996). Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheumatism 39:1951–60
- Csordas K, Lautner-Csorba O, Semsei AF, et al. (2014). Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Brit J Haematol 166:410–20
- Dervieux T, Greenstein N, Kremer J. (2006). Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheumatism 54:3095–103
- Dervieux T, Kremer J, Lein DO, et al. (2004). Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenet Genomics 14:733–9
- Einollahi N, Alizadeh S, Dashti N, et al. (2013). Serum lipid profile alterations in acute leukemia before and after chemotherapy. IJBC 6:3–9
- Eissa DS, Ahmed TM. (2013). C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 24:181–8
- Evans WE, Crom WR, Abromowitch M, et al. (1986). Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. New Engl J Medicine 314:471–7
- Evans WE, Relling MV. (2004). Moving towards individualized medicine with pharmacogenomics. Nature 429:464–8
- Evans WE, Relling MV, Rodman JH, et al. (1998). Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med 338:499–505
- Gleiβner B, Gökbuget N, Bartram CR, et al. (2002). Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536–43
- Jahedi M, Shamsasenjan K, Sanaat Z, et al. (2014). Aberrant Phenotype in Iranian Patients with Acute Myeloid Leukemia. Adv Pharm Bull 4:43
- Jemal A, Murray T, Ward E, et al. (2005). Cancer statistics, 2005. Cancer J Clinicians 55:10–30
- Koomdee N, Hongeng S, Apibal S, Pakakasama S. (2012). Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev 13:3461–4
- Liu Y, Yin Y, Sheng Q, et al. (2014). Association of ABCC2− 24C> t polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PloS one 9:e82681
- Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. (2013). A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 13:498–506
- Mancini M, Scappaticci D, Cimino G, et al. (2005). A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 105:3434–41
- Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, et al. (2010). Polymorphisms of the γ-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leukemia Res 34:728–32
- Pu C.-H, Evans WE. (2006). Treatment of acute lymphoblastic leukemia. New Engl J Med 354:166–78
- Pui C.-H, Gaynon, PS, Boyett JM, et al. (2002). Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909–15
- Sharifi MJ, Bahoush G, Zaker F, et al. (2014). Association of-24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 31:169–77
- Shimasaki N, Mori T, Torii C, et al. (2008). Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol/Oncol 30:347–52
- Vanasse GJ, Concannon P, Willerford DM. (1999). Regulated genomic instability and neoplasia in the lymphoid lineage. Blood 94:3997–4010
- Wood AJ, Evans WE, Mcleod HL. (2003). Pharmacogenomics – drug disposition, drug targets, and side effects. New Engl J Med 348:538–49